e-mailprint

Terumo Cardiovascular Systems Broadens Product Portfolio Through Distribution Agreement with Pall Medical

ANN ARBOR, Mich. — August 29, 2002 — Terumo Cardiovascular Systems Corporation (Terumo CVS) and Pall Medical announced that they have signed a distribution agreement appointing Terumo CVS the exclusive distributor for Pall cardiovascular products in North, Central, and South America beginning September 1st, 2002, and in Europe beginning October 1st, 2002. Pall cardiovascular products include a variety of filters used in the extracorporeal circuit during heart surgery to remove micro-air and other embolic particles from the blood.

Terumo CVS manufactures, markets, and sells monitoring systems and cardiopulmonary bypass products for U.S. and other global cardiac surgery markets. It has been actively engaged in expanding its product portfolio through partnerships and acquisitions as well as internal development. In the last two years, the company has arranged distribution of complementary products with medical device manufacturers Fresenius Hemocare, Aesculap, and Spencer Technologies. It has also acquired product lines and production facilities from Lifestream International.

"This partnership with Pall Medical will benefit both companies as well as our customers," states Mark Sutter, President and CEO of Terumo Cardiovascular Systems.

"We expect that the patented technologies of both companies, such as Pall's LeukoGuard™ filters and Terumo's X Coating™, will work synergistically to improve cardiopulmonary bypass," agrees Nicolas Gikakis, Director, Extracorporeal Products for Pall Medical.

Terumo Cardiovascular Systems Corporation is a subsidiary of Terumo Corporation of Tokyo, Japan. It is headquartered in Ann Arbor, Michigan with manufacturing operations in Ann Arbor, as well as Elkton, Maryland; Ashland, Massachusetts; Tustin, California; and Matamoros, Mexico. Terumo Corporation is a premier global medical company with 2001 annual sales in excess of $1.7 billion. Terumo Corporation develops manufactures, and markets a wide range of medical products including syringes, needles, catheters, and blood bags.

Pall Corporation is the global leader in the rapidly growing fields of filtration, separations and purification. Pall's business is organized around two broad markets: Life Sciences and Industrial. The Company provides leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceuticals, transfusion medicine, semiconductors, municipal drinking water and aerospace. Pall is actively developing partnerships with companies that provide complementary services and technologies. Total revenues are $1.5 billion, after giving effect to the FSG acquisition. The Company is headquartered in East Hills, New York and has major operations in more than 30 countries. Further information is available at http://www.pall.com.